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Background: Nasopharyngeal carcinoma (NPC) is well-known for its highly metastatic characteristics, but little is
known of its molecular mechanisms. New biomarkers that predict clinical outcome, in particular the ability of the
primary tumor to develop metastatic tumors are urgently needed. The aim of this study is to investigate the role of
FLJ10540 in human NPC development.
Methods: A bioinformatics approach was used to explore the potentially important regulatory genes involved in
the growth/metastasis control of NPC. FLJ10540 was chosen for this study. Two co-expression strategies from NPC
microarray were employed to identify the relationship between FLJ10540 and osteopontin. Quantitative-RT-PCR,
immunoblotting, and immunohistochemistry analysis were used to investigate the mRNA and protein expression
profiles of FLJ10540 and osteopontin in the normal and NPC tissues to confirm microarray results. TW01 and Hone1
NPC cells with overexpression FLJ10540 or siRNA to repress endogenous FLJ10540 were generated by stable
transfection to further elucidate the molecular mechanisms of FLJ10540-elicited cell growth and metastasis under
osteopontin stimulation.
Results: We found that osteopontin expression exhibited a positive correlation with FLJ10540 in NPC microarray.
We also demonstrated comprehensively that FLJ10540 and osteopontin were not only overexpressed in NPC
specimens, but also significantly correlated with advanced tumor and lymph node-metastasis stages, and had a
poor 5-year survival rate, respectively. Stimulation of NPC parental cells with osteopontin results in an increase in
FLJ10540 mRNA and protein expressions. Functionally, FLJ10540 transfectant alone, or stimulated with osteopontin,
exhibited fast growth and increased metastasis as compared to vehicle control with or without osteopontin
stimulation. Conversely, knockdown of FLJ10540 by siRNA results in the suppression of NPC cell growth and
motility. Treatment with anti-CD44 antibodies in NPC parental cells not only resulted in a decrease of FLJ10540
protein, but also affected the abilities of FLJ10540-elicited cell growth and motility in osteopontin stimulated-NPC
cells.
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Conclusions: These findings suggest that FLJ10540 may be critical regulator of disease progression in NPC, and the
underlying mechanism may involve in the osteopontin/CD44 pathway.
Keywords: Nasopharyngeal carcinoma, FLJ10540, Osteopontin, CD44Background
Nasopharyngeal carcinoma (NPC), the most common
head and neck cancer, is a disease in which malignant
cells form in the epithelium of the nasopharyngeal cav-
ity. There is a high incidence of NPC in southern China
and Southeast Asia, where the annual incidence is more
than 20–30 cases per 100,000 people [1], and this pat-
tern persists in those who have emigrated. The etiology
of NPC seems to follow a multistep process, in which
EBV infection, ethnic background, consumption of food
and alcohol, and environmental carcinogens all seem to
play a role [2]. Advances in diagnostic imaging, radiation
therapy, and concurrent chemoradiotherapy have
achieved better locoregional control, however final treat-
ment outcomes are not satisfactory [3,4].
The process of metastasis which is considered a late
event in tumorigenesis is very complex. Due to the rapid
growth behavior of NPC, it has a high tendency to invade
adjacent regions and metastasize to regional lymph nodes
and distant organs [5-7]. More than 60% of NPC patients
are first diagnosed with metastasis, leading to a high rate
of treatment failure [6]. The prognosis of NPC depends
primarily on clinical TNM staging and tumor size [8].
However, NPC patients with the same clinical stage often
have different clinical courses, suggesting that TNM sta-
ging and tumor size are insufficient to accurately predict
prognosis [9]. Thus it is important to search for new
therapeutic targets and a better understanding of the
mechanisms involved in the spread of NPC.
Osteopontin, also known as SPP-1, was first detected
in 1979 from malignantly transformed epithelial cell
lines and T cells [10]. Human osteopontin is composed
of 314 amino acid residues containing two crucial func-
tional domains, the calcium-binding domain and
arginine-glycine-aspartic acid (RGD) sequences [11]. It is
a multifunctional cytokine which mediates in bone re-
sorption, atherosclerosis, angiogenesis, wound repair,
immune function, tissue injuries, and disease formation
[12,13]. Osteopontin expression has been associated with
cancer markers for many years [14]. Strong osteopontin
expression in tumor cells has been shown in a variety of
cancer types and is associated with poor prognosis and
metastasis including gastric, ovarian, lung, breast, pros-
tate, liver, sarcomas, colon, renal, and head and neck
cancers [15-18]. However, the precise role of osteopontin
in tumor development and promoting cancer metastasis
in NPC is largely unknown.FLJ10540 is also known by other names, including
CEP55 [19], and C10orf3 [20]. FLJ10540 is overex-
pressed in human colon cancer [20], hepatocellular car-
cinoma (HCC) [21], lung cancer [22] and oral cavity
squamous cell carcinoma (OCSCC) [23], suggesting that
it may function as an oncogenic characteristics in tumor
development. However, there is little information regard-
ing the expression and significance of FLJ10540 with
tumor histological grade, stage, and patient outcome in
NPC patients. In addition, the precise roles of FLJ10540
in tumor growth and metastasis in NPC are large un-
known. The purpose of the present study was to exam-
ine the expression levels of FLJ10540 in NPC specimens,
and to correlate the results with clinicopathologic vari-
able survival and to investigate the functional role of
FLJ10540 in human NPC development.Methods
Patients and tumor samples
To measure the expression of the FLJ10540 and osteo-
pontin transcripts in NPC tissues, fresh tissues were
obtained from patients with NPC biopsy specimens.
Controls included fresh normal nasopharyngeal mucosal
tissues from other patients with biopsies for other non-
neoplastic diseases. These materials were histologically
confirmed by frozen sections before quantitative RT-
PCR and western blotting assays. Available paraffin-
embedded tissue blocks were retrieved from 63 NPC
patients. Clinicopathological information for each sub-
ject, including gender, age, tumor-(T) stage, nodal-(N)
status, TNM stage, and disease-specific survival (DSS),
was obtained retrospectively from clinical records and
pathology reports. NPC patients received local head and
neck examinations before treatment, along with staging
examinations, including whole body bone scans, abdom-
inal ultrasonography, computed tomography, and/or
magnetic resonance imaging. Using the 2002 American
Joint Committee on Cancer staging system, 19 patients
were classified as T1, 25 as T2, four as T3, and 15 as T4.
Twenty-eight patients were classified as N0, 13 as N1,
18 as N2, and four as N3. Twelve patients were deter-
mined to be at stage I, 20 at stage II, 11 at stage III, and
20 at stage IV. The method of radiotherapy for NPC
was, in general, uniform throughout this period. All
patients were regularly monitored after receiving radio-
therapy and/or chemotherapy until death or their last
appointment, according to the intervals and protocols of
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data were either obtained from the cancer registry of our
hospital or collected from the patients’ attending physi-
cians. Locoregional failure was determined by patho-
logical diagnosis or progressive deterioration, as shown
on consecutive imaging studies. To identify distant me-
tastases, patients underwent chest radiography yearly
and bone scans or abdominal ultrasonography whenever
indicated. All study participants provided informed con-
sent, and study design was approved by the Medical Eth-
ics and Human Clinical Trial Committee of Chang
Gung Memorial Hospital.
RNA extraction, and quantitative RT-PCR (Q-RT-PCR)
Tissue samples were frozen in liquid nitrogen and stored
at −80°C prior to RNA extraction. The RNA extraction,
and quantitative RT-PCR assays were performed as
described previously [4]. For Q-RT-PCR, FLJ10540 and
osteopontin Taq-Man probes (ABI) were used. Data were
represented as mean ± s.d. To analyze the distribution
of normal and tumor areas, we used the Wilcoxon
signed rank test between two groups for statistical ana-
lysis. A P-value of less than 0.05 was considered statisti-
cally significant. GAPDH was used as an internal control
for comparison and normalization of the data. Assays
were performed in triplicate using an Applied Biosys-
tems Model 7500-Fast instrument.
Immunoblot analysis
For tissue protein extraction, frozen samples were
homogenized in RIPA lysis buffer (50 mM Tris–HCl, pH
7.5, 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate,
and 0.1% SDS). The western blotting assay was per-
formed as described previously [4]. The antibodies used
in this study included polyclonal antibodies against
FLJ10540 (generated by us) [23], HA (3F10, Roche Bio-
chemicals, Indianapolis, IN, USA), and β-actin (mono-
clonal; Santa Cruz Biotechnology, Santa Cruz, CA,
USA). The proteins were investigated using X-ray films.
Immunohistochemical study
Normal and tumor NPC tissue samples were selected by
a pathologist based on diagnosis and microscopic
morphology. Immunohistochemical staining was per-
formed as described previously [4,23,24]. After antigen
retrieval, the sections were incubated with diluted anti-
FLJ10540 antibody (polyclonal; generated by us;
1:200; polyclonal; Abnova, Taiwan 1:100), and anti-
osteopontin (polyclonal; Abnova, Taiwan 1:100; poly-
clonal; Santa Cruz Biotechnology, Santa Cruz, CA,
USA; 1:50 at room temperature for 1 hour, followed
by washing with PBS. Horseradish peroxidase/Fab
polymer conjugate (PicTure™-Plus kit; Zymed, South
San Francisco, CA, USA) was then applied to thesections for 30 min followed by washing with PBS.
Finally, the sections were incubated with diamino-
benzidine for 5 min to develop the signals. A nega-
tive control was run simultaneously by omitting the
primary antibody. The reactivity level of the immu-
nostained tissues was evaluated independently by
two pathologists who were blind to the subjects’
clinical information. Between 15 and 20 high-power
fields were viewed. Criteria were developed for quan-
titating the immunoreactivities of the osteopontin
staining in both the normal and tumor sections
using a score range of 0 to +3, where 0 indicated no
positive cell staining, +1 less than 5% positive cell
staining, +2 5-50% positive cell staining, and +3
more than 50% positive cell staining. Similarly, the
stain intensity was graded as +0, +1, +2, or +3 as
previously described [25]. The quantitating of the
immunoreactivities of the FLJ10540 staining followed
the protocol of osteopontin. High-expressions of
FLJ10540 and osteopontin were defined as +2 or
higher for both scoring methods.
Cell culture, establishment of stable clones, gene
silencing using siRNA, promoter plasmids, and luciferase
assays
NPC-TW01 and Hone-1 cell lines derived from primary
nasopharyngeal tumors of untreated NPC patients were
used for functional assays [26-28]. All cell culture-related
reagents were purchased from Gibco-BRL (Grand Island,
NY, USA). TW01 cells were grown in DMEM, however the
Hone1 cells were grown in RPMI containing 10% FBS and
100 U/ml penicillin and streptomycin (Gibco-BRL). HA-
vector (pcDNA3.1), and HA-FLJ10540 were transiently
transfected into cancer cells using Lipofectamine (Invitro-
gen) according to the manufacturer’s instructions. TW01
and Hone1 cells stably expressing FLJ10540 were selected
with 400 μg/ml G418 (Calbiochem Novabiochem, San
Diego, CA, USA). The cells were then harvested and ana-
lyzed for exogenous FLJ10540 expression by Western blot-
ting. 5’-upstream fragments of FLJ10540 gene was amplified
from human genomic DNA and verified by sequencing.
The PCR fragments were cloned into firefly luciferase re-
porter vector pGL3-Basic (Promega) NheI and HindIII sites
which were designed into the forward and the reverse pri-
mers, respectively. pRL-TK (Promega), a Renilla luciferase
internal control vector, was used for normalization of firefly
luciferase signals. For co-transfection experiments, TW01
cells were co-transfected with 100 ng firefly luciferase re-
porter plasmids (pGL3-Basic or pGL3-FLJ10540) and 10 ng
of pRL-TK Renilla luciferase internal control plasmid. After
24h, the cells were incubated with serum-free medium for
18h after osteopontin was added. The Luciferase activity
was measured using Dual Glo™ Luciferase Assay System
(Promega), One double-stranded synthetic RNA oligomers
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from human FLJ10540 and one negative control siRNA
(#4611G; Ambion) were used in the siRNA experiments.
The specific protein levels were determined by Western
blotting analysis with specific antibodies.
Cell viability assay
The viability of sub-confluent cells was analyzed by 3-
(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) reduction assay. The assay was performed in
96-well plates seeded with 4000–6000 cells/well in 200 μl.
After 24 hours, 100 μl of culture medium containing 25 μl
MTT solutions was added (1 g MTT (Sigma M5655) dis-
solved in 200 mL D-PBS). It was stored for 4 hours at
37°C, and then 100 μl DMSO buffer was added and left
protected from light for 10 min. Readout was performed
using a microplate reader (Labsystems Multiscan MCC/
340) at 540 nm. Absorbance at 692 nm was used as the
reference.
Migration and invasion assays
Migration and invasion assays were conducted with
TW01-/Hone1-vehicle, TW01-/Hone1-FLJ10540, TW01-
negative, and TW01-siFLJ10540 stable clones using
24-well Transwell chambers (8-μm pore size polycarbon-
ate membrane; Costar). The migration and invasion
assays were performed as described previously [4,23,24].
Briefly, cell migration and invasion were evaluated by
counting the number of TW01-/Hone1-vehicle, TW01-/
Hone1-FLJ10540, TW01-negative, and TW01-siFLJ10540
stable clone cells that had migrated or invaded by 200X
phase-contrast microscopy on three independent mem-
branes, then normalized against the vehicle cells to deter-
mine the relative ratio.
Microarray analysis, data analysis and clustering
algorithm
The microarray data of NPC (GEO Series accession num-
ber is GSE12452) has been deposited in NCBIs Gene Ex-
pression Omnibus (GEO) and were analyzed using
GeneSpringW 7.3.1 software (Silicon Genetics, Redwood
City, CA). The microarray data was normalized by Robust
Multichip Average (RMA) algorithm to produce and
normalize the Affymetrix expression signals for the tran-
scripts based on corresponding probe pairs of oligonucleo-
tides. One-way analysis of variance (ANOVA) was used to
build an explicit model about the sources of variances that
affect the measurements. The values of p< 0.05 were con-
sidered as statistically significant.
Statistical analyses
Several clinicopathological factors were evaluated, in-
cluding gender, age, T stage, N status, and TNM stage.
Fisher’s exact test was used to evaluate the correlationbetween the clinicopathological variables and the expres-
sions of FLJ10540 and osteopontin. A p value of less
than 0.05 was considered to indicate statistical signifi-
cance in all analyses. Clinicopathological variables and
the expression of FLJ10540 and osteopontin were taken
into account for the analysis of survival, based on the
Kaplan-Meier method; statistical significance, defined as
a p value of less than 0.05, was assessed by log-rank test.
To determine the effect of particular prognostic factors
on survival, a multivariate analysis was performed
according to Cox’s regression model.
Results
Elevated FLJ10540 expression in NPC tissues
A significant challenge in the post-genomic era is deter-
mining how to prioritize differentially expressed and
poorly characterized targets in cancer-related microarray
profiling studies. This study aimed to identify and
characterize novel oncogenes that are only conserved in
vertebrates, but not in invertebrates, based on the hy-
pothesis that these novel genes may possess unique
function in human cancer development. We used a bio-
informatics approach to search for potentially important
regulatory genes involved in growth control of human
NPC. The publicly accessible microarray data has been
deposited in NCBIs Gene Expression Omnibus (GEO)
but can be accessed through the GEO Series accession
number GSE12452 [29]. According to the microarray
data of 31 primary NPC specimens, 592 out of 54,675
differentially expressed transcripts between normal and
tumor areas were clustered by the ANOVA (p<0.05)
based on three-fold differences and tested using the Ben-
jamini and Hochberg false discovery rate correlation
(p<0.05). These molecular portraits, containing 193 up-
regulated and 399 down-regulated transcripts, could
successfully distinguish the patients’ normal and tumor
areas by hierarchical clustering (Additional file 1: Figure
S1). As a result, we focused on the poorly characterized
gene, FLJ10540. FLJ10540 exhibited up-regulated expres-
sion patterns in NPC specimens in microarray database
(Figure 1A). To validate the gene expression profile data
for FLJ10540, Q-RT–PCR was performed on 12 NPC-
tumor and five normal tissue samples. Figure 1B shows
that overexpression of FLJ10540 was observable in our
NPC patient samples. This result raises the possibility
that upregulation of FLJ10540 may lead to the abnormal-
ities found in human NPC.
Using the concept of syn-expression to uncover
osteopontin, as the upstream regulator of FLJ10540 in
NPC specimens
Using the concept of syn-expression, genes belonging to
the same pathway often show the same regulatory pro-
files under a variety of biological situations [30]. Hence,
Figure 1 FLJ10540 was highly correlated with osteopontin
expression in human NPC specimens. (A) The microarray
expression patterns of FLJ10540 in NPC patients were normalized
against the expression patterns on HG_U133 plus 2.0 chips. The
boxplot shows the data distribution as a grouping classification and
indicates that there was a statistically significant difference
(p<0.0001) between the tumor tissues and the normal tissues from
NPC patients. (B) The mRNA expression levels of FLJ10540 and
osteopontin from twelve NPC patients and five normal tissues were
determined by Q-RT-PCR. The results were normalized against the
expression levels of GAPDH mRNA in each sample. N: normal tissues;
T: tumor tissues. (C) Western blotting analysis of FLJ10540 and
osteopontin expressions were performed in seven NPC samples and
two normal tissues. Total proteins were extracted from respective
tissues and probed with antibodies against FLJ10540 and
osteopontin. β-actin was used as a control.
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dataset, as described earlier, to gain insight into the
functional concordance of co-expressed genes. To test
this hypothesis, we first examined whether the mRNA
expression profile of FLJ10540 correlated with any ligand
in the publicly accessible microarray database of NPC.
Of these co-expressed genes, the top candidate was
osteopontin, which was highly positively correlated with
the mRNA expression level of FLJ10540 in NPC cancerpatients (r=0.72 p<0.001). This raises the possibility that
these two molecules are functionally linked or in the
same pathway.
The same panels of 12 NPC-tumor and five normal
tissues were also applied to examine the mRNA expres-
sion level of osteopontin by Q-RT-PCR. As shown in
Figure 1B, the mRNA expression levels of osteopontin
were increased in the tumor samples as compared to
those in normal tissue samples. The expressions of
FLJ10540 and osteopontin in another batch of freshly
frozen tumor and normal samples were further verified
by western blotting. Our data indicated that the western
blot results were consistent with the observed mRNA
expressions of FLJ10540 and osteopontin in NPC speci-
mens (Figure 1C). Taken together, these results suggest
that there is a significant positively correlation between
FLJ10540 and osteopontin in human NPC.
To investigate the clinical implications of FLJ10540
and osteopontin in NPC, immunohistochemical analysis
was performed to determine the expressions and distri-
butions of FLJ10540 and osteopontin in 63 human NPC
samples and 10 normal tissues. The representative
results of FLJ10540 and osteopontin immunostaining in
NPC are shown in Figure 2A. First, FLJ10540 and osteo-
pontin revealed very weak but detectable staining in the
epithelium (Figure 2A, a and f). In the tumor samples,
FLJ10540 and osteopontin expressions were positively
correlated with tumor stage and node stage of the tumor
cells (Figure 2A, b-e and g-j). However, strong stainings
were not observed in tumor tissues when anti-FLJ10540
and anti-osteopontin antibodies were pre-incubated with
protein corresponding to a portion of FLJ10540 and
osteopontin, respectively (data not shown). Third,
FLJ10540 and osteopontin were largely localized in the
cytoplasm of the tumor sample cells as well as in normal
tissues. To further confirm our immunohistochemisty
results, anti-FLJ10540 and anti-osteopontin antibodies
from Abnova produced almost the same results. In
Figure 2 Immunohistochemical staining for FLJ10540 and osteopontin and overall survival in patients with NPC. (A) The FLJ10540 and
osteopontin intensities in various tissues were evaluated by immunohistochemical staining. FLJ10540 and osteopontin immunohistochemical
staining intensities are shown in tumor and normal tissues. Normal tissues displayed very weak FLJ10540 and osteopontin staining in the
cytoplasm (a, and f). The stainings for FLJ10540 and osteopontin were higher in tumor tissues (b-e and g-j). Significant cytoplasm expressions of
FLJ10540 and osteopontin were observed in early (b, and g) and late (c, and h) stage tumors. Original magnification ×100. (B) The survival period
of those patients (n=63) with strong expressions of FLJ10540 and osteopontin (dashed lines) were significantly shorter than for those with lower
expressions of FLJ10540 and osteopontin (solid line). The difference in survival was statistically significant (p<0.001) according to the log-rank test.
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Table 1 χ2 test was done to assess the association
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tween FLJ10540 and osteopontin. As shown in Table 1,
FLJ10540 again was significantly associated with osteo-
pontin. Taken together, these results suggest that
patients with a high FLJ10540 score had a significantly
higher osteopontin score in human NPC.
Prognostic value of FLJ10540 and osteopontin expression
levels in NPC
As shown in Table 2, patients with stage III-IV tumors, a
higher rate of lymph node metastasis, and TNM stages III-
IV had significantly higher expressions of FLJ10540 or
osteopontin compared with patients with stage I-II tumors
(p<0.001), with no or a lower rate of lymph node metasta-
sis (p=0.001 and p=0.007), and TNM stages I/II (p<0.001).
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WHO type II 25 12










Abbreviations: NPC naso-pharyngeal carcinoma; WHO World Healthy Organization;
a p-value from Chi-square or Fisher exact test. Statistically significant (p < 0.05).FLJ10540 and osteopontin were observed in terms of the
patients’ age, gender, or histological type at the time of diag-
nosis. These findings suggest that both FLJ10540 and osteo-
pontin expressions correlate with higher tumor progression
from an early stage to advanced stage.
A DSS analysis using the Kaplan-Meier methods
revealed that the prognosis of patients with high tumor
expressions of FLJ10540 and osteopontin were signifi-
cantly poorer than that of patients with low tumor
expressions of FLJ10540 and osteopontin (p<0.001)
(Figure 2B). Univariate analysis showed that DSS in this
series was significantly associated with several clinico-
pathological factors, including T (p<0.001), N (p=0.009),
and TNM stage (p=0.001) (Table 3). Clinical prognosis,
however, was not associated with age, gender or histo-
logical type. For multivariate analysis, however, T stage
(p<0.001; hazard ratio = 5.091) remained significant in-
dependent prognostics factor of DSS for NPC patients.
These results clearly indicate that the 5-year survival
and clinical prognosis of NPC are associated with
FLJ10540 and osteopontin expressions in NPC patients.
Osteopontin triggered FLJ10540 expression in NPC cancer
cells
As shown in the Figure 3A, the mRNA and protein ex-
pression levels of FLJ10540 were increased in an osteo-ns between the subgroups of various clincopathological





















AJCC American Joint Committee on Cancer.a
Table 3 Disease-specific survival by Cox regression analyses between the subgroups of various clincopathological
parameters
Parameters No No of events HR (95% CIa) p-valueb
Age (years) 1.695 (0.743-3.875) 0.211
<50 24 8
≥ 50 39 19
Gender 0.596 (0.225-1.575) 0.297
Male 47 22
Female 16 5
Histology 0.930 (0.431-.006) 0.854
WHO type II 37 16
WHO type III 26 11
Primary tumor (T) 5.091 (2.350-11.030) <0.001
T1-T2 44 12
T3-T4 19 15
Nodal status (N) 2.780 (1.302-5.934) 0.009
N0-N1 41 13
N2-N3 22 14
AJCC staging 4.464 (1.879-10.607) 0.001
Stage I-II 31 7
Stage III-IV 32 20
FLJ10540 4.741 (2.177-10.326) <0.001
Low expression 42 11
High-expression 21 16
Osteopontin 5.012 (2.315-10.850) <0.001
Low expression 47 14
High-expression 16 13
Abbreviations: HR Hazard Ratio, WHO World Healthy Organization; AJCC American Joint Committee on Cancer.
a 95% Wald Confidence Limits.
b Associations determined by Cox regression analyses. Statistically significant (p < 0.05).
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PCR and Western blotting. Similar results were also
obtained in the Hone1 cells (Figure 3B). Next, to investi-
gate the role of osteopontin in regulating FLJ10540 tran-
scription, we sought to determine whether FLJ10540
promoter activity could be regulated by osteopontin
stimulation. We transfected the FLJ10540 promoter-
luciferase constructs into TW01 cells following osteo-
pontin stimulation in a dose-dependent manner. The
data showed that a significant activation of the FLJ10540
promoter was detected under osteopontin stimulation
(Figure 3C). These results illustrated that FLJ10540 is
one of the downstream targets of the osteopontin signal-
ing pathway in human NPC cancer cells.
FLJ10540 transfectants alone or stimulated with
osteopontin could promote cell growth in NPC
In Figure 2A, FLJ10540 expression is significantly higher
in the NPC patients with a late tumor stage. This raisesthe possibility that FLJ10540 expression may promote
tumor growth in NPC. Two different cell types were
employed to address this question. First, TW01 and
Hone1 cells stably expressing HA-tagged FLJ10540 were
established (Figure 4A and B, left panel). FLJ10540-
TW01 stable transfectants or vehicle control cells were
seeded in 96-well plates to test whether they could grow
in low serum medium. The results showed that
FLJ10540-TW01 stable transfectants could promote cell
growth in low-serum media compared to the vehicle
control (Figure 4A, right panel). Similar results were also
observed in FLJ10540-Hone1cells (Figure 4B, right
panel). To determine whether osteopontin contributes
to FLJ10540-mediated cell growth, FLJ10540-NPC trans-
fectants, and vehicle control in the presence of osteo-
pontin stimulation were seeded in 96-well plates to test
cell proliferation. The results showed that FLJ10540-
NPC stable transfectants in the presence of osteopontin
grew faster than the vehicle control with osteopontin
Figure 3 FLJ10540 was up-regulated by osteopontin stimulation in human cancer cells. (A and B, left panel) The mRNA expression level of
FLJ10540 was determined by Q-RT-PCR in TW01, and Hone1 cells with a dose-dependent manner of osteopontin. The results were normalized
against the expression level of GAPDH mRNA in each osteopontin-treated cell. (A and B, right panel) The protein expression level of FLJ10540
was determined by Western blotting in TW01, and Hone1 cells. After treatment with various concentrations of osteopontin for 30 min, the total
protein was extracted and the cell lysates (50 μg) of each treated cell were subjected to immunoblot analysis with anti-FLJ10540 and β-actin
antibodies. β-actin was used as a control. Data are representative of three independent experiments done in triplicate. (C) Luciferase assays were
done to detect promoter activity of FLJ10540 in transfected TW01 cells in the presence or absence of osteopontin. The luciferase activity in 1μg
of cell lysate was normalized to β-galactosidase activity. Data are representative of three independent experiments done in triplicate.
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we also found that stimulated FLJ10540 transfectants
with osteopontin was also growth faster than FLJ10540
stable cells alone. Taken together, these results suggest
that FLJ10540 transfectants with or without osteopontin
stimulation may decrease the requirement for serum, a
characteristic of transformed cells.Knockdown of endogenous FLJ10540 by siRNA
suppressed NPC cell growth
We used a siRNA approach to inhibit endogenous expres-
sion of FLJ10540, and assayed for the growth rate of NPC
cells. First, we transfected a chemically synthesized
FLJ10540 siRNAs (siFLJ10540) and a negative control into
TW01 and Hone1 for 24 hours, followed by Western blot
Figure 4 Osteopontin enhanced FLJ10540-NPC transfectants to promote cell proliferation. (A and B, left panel) HA-tagged FLJ10540-stable
clones of TW01 and Hone1 cells were established. The cell lysates were subjected to an immunoblot analysis with an anti-HA antibody. (A and B,
right panel) Vehicle-TW01/-Hone1 and FLJ10540-TW01/-Hone1 stable transfectants with or without osteopontin (OPN) stimulation were seeded
into 96-well plates with 1.0% of FBS. The cells were cultured for 1–3 days followed by MTT assay (OD570) to quantitate cell growth. The data
were normalized against the OD570 value on day 1 of each treatment. The growth curve of TW01 and Hone1 cells are shown as the mean ±s.d.
of three independent experiments.
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showed a dramatic reduction in the FLJ10540 protein level
with FLJ10540 siRNA (Figure 5A and B, left panel). Both
TW01 and Hone1 siFLJ10540-transfected and negative
control were determined the growth rates by MTT assay.
The results demonstrated that the proliferation rate of
FLJ10540 siRNA transfected cells was much slower than
the cells transfected with negative siRNA (Figure 5A and
B, right panel). Using the same panel, we also asked
whether osteopontin encourages cell growth in depleted-
FLJ10540 NPC cells. The result showed that FLJ10540-
depleted NPC cells had a slight increased growth curve
under osteopontin stimulation, compared to siFLJ10540
alone (Figure 5A and B, right panel). Take together these
results strongly supports the idea that FLJ10540 plays a
role in the cell proliferation of NPC cells.
FLJ10540 and osteopontin synergistically induced the
migration and invasion of NPC cancer cells
FLJ10540 expression was higher in the NPC patients with
lymph node metastasis (N+) than those that withoutlymph node metastasis (N-) (Figure 2A). We hypothesized
that FLJ10540 may participate in the progression of me-
tastasis in cells. FLJ10540-TW01 stable cells and vehicle
control were seeded on a Transwell chamber to perform a
motility assay for migration and invasion. Quantitatively
speaking, the migration ability of FLJ10540-TW01 stable
transfectants was approximately 4.8-5.5-fold higher than
that of the vehicle control (Figure 6A, left panel). We next
performed an invasion assay using a Matrigel-coated
barrier filter. After 24 hours of incubation in the
Matrigel-coated Transwell chamber, the TW01-FLJ10540
transfectants had invaded the basement membrane mater-
ial and passed through the pores to reach the underside of
the filter. Similarly, the TW01-FLJ10540 expressing cells
showed a 6.8-7.8-fold higher invasive ability than the ve-
hicle control cells (Figure 6A, right panel). The overex-
pressed FLJ10540 stable transfectants in the presence of
osteopontin stimulation were analyzed the cell motility in
a Transwell chamber. Again, FLJ10540 transfectants with
osteopontin stimulation had a higher migration and inva-
sion abilities than that the FLJ10540 alone or vehicle
Figure 5 Osteopontin reversed the cell growth inhibition of siFLJ10540-NPC. (A and B, left panel) A negative control (NC) siRNA plus one
different FLJ10540 siRNA (siFLJ10540) were transfected into TW01 and Hone1 cells for 24 hours. After transfection, Western blotting was
performed using anti-FLJ10540 and β-actin antibodies. (A and B, right panels) Using the same panel, the siFLJ10540 transfectants and NC with or
without osteopontin (OPN) stimulation were seeded into 96-well plates with 1.0% of FBS. The cells were cultured for 1–3 days followed by MTT
assay (OD570) to quantitate cell growth. The data were normalized against the OD570 value on day 1 of each treatment. The growth curve of
TW01 and Hone1 cells are shown as the mean ±s.d. of three independent experiments.
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http://www.translational-medicine.com/content/10/1/93control (Figure 6A). Conversely, the motility of the NPC
cells was strongly inhibited, while endogenous FLJ10540
was depleted by siRNA (Figure 6B). However, compared
with siFLJ10540-NPC cells, the migratory and invasive
abilities of siFLJ10540-NPC cells were slightly increased
after cell-treated with osteopontin (Figure 6B). Taken to-
gether, these results strongly suggest that FLJ10540 is
required for proper osteopontin-dependent signaling, and
that it contributes to cell migration and invasion in NPC.
Osteopontin-mediated FLJ10540 expression promoted
cell proliferation and motility via CD44
We next asked whether the involvement of CD44 on the
biological activities of osteopontin could be attributed to
the modulation of FLJ10540 expression induced by
osteopontin in NPC cancer cells. The CD44 receptors
were blocked using neutralizing antibodies, and analyzed
FLJ10540 protein expression in TW01 cells upon osteo-
pontin stimulation. The results demonstrated that upre-
gulation of FLJ10540 in the presence of osteopontin wasinhibited by the simultaneous addition of CD44 anti-
bodies in a dose-dependent manner (Figure 7A). Similar
results were also observed in Hone1 cells (data not
shown). To confirm the involvement of CD44 in mediat-
ing FLJ10540 function upon osteopontin stimulation, we
treated FLJ10540-TW01 and vehicle cells with anti-
CD44 blocking antibody or isotypes IgG antibody in the
presence of osteopontin and monitored cell growth and
motility. Anti-CD44 antibodies resulted in a significant
inhibition of cell growth and motility by FLJ10540 stable
cells in the presence of osteopontin stimulation, com-
pared to FLJ10540 stable cells treated with isotype IgG
antibody (Figure 7B, and C). Taken together, these
results indicate that FLJ10540 is required for proper
osteopontin/CD44-dependent signaling and that it con-
tributes to cell proliferation and metastasis.
Discussion
Our data illustrates that the up-regulation of FLJ10540
and osteopontin expressions are associated with a poor
Figure 6 FLJ10540 alone or increased FLJ10540, mediated by osteopontin stimulation modulated cell migration and invasion in NPC
cells. (A and B) For the migration assays, 5 × 103 cells (Vehicle-TW01, FLJ10540-1-TW01, FLJ10540-2-TW01, negative control, and siFLJ10540-TW01)
with or without osteopontin (OPN) stimulation were seeded into the top of a Transwell insert. After 24 hours, the cells on top were scraped, and
the cells that had migrated to the bottom were fixed and stained with Giemsa. For the invasion assays, 1 × 104 cells were seeded after the
addition of Matrigel. The relative-fold migration/invasion values for the stable clones were normalized against the vehicle/negative control cells
and are represented diagrammatically. All of the data represent the mean ± s.d. of three independent experiments.
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http://www.translational-medicine.com/content/10/1/93prognosis in NPC patients. It is worth noting that prog-
nosis was not dependent on histologic type, but rather
dependent on the expressions of FLJ10540 and osteo-
pontin. FLJ10540 and osteopontin positively correlated
with a poor prognosis in NPC patients, especially with T
and N stages respectively. Because it is difficult to pre-
dict the prognosis of such patients, investigating
FLJ10540 and osteopontin stainings together in NPC
cancer cells may be helpful in determining the thera-
peutic strategy. Functionally, Ectopic expression of
FLJ10540 enhanced cell growth, migration and invasion.
Conversely, siRNA-mediated repression of FLJ10540
suppressed cell growth and motility in NPC. Moreover,blocked CD44 receptors by using CD44-specific anti-
bodies, not only decreased the protein expression of
FLJ10540 under osteopontin stimulation, but also sup-
pressed FLJ10540-elicited NPC cell growth and metasta-
sis, supporting the participation of FLJ10540 in the
osteopontin/CD44 pathway. These findings suggest that
FLJ10540 is not only a good prognostic indicator of
NPC, but also a candidate for a molecular targeted
therapy.
FLJ10540 overexpression is disclosed in a number of
human cancers and cell lines, and has been correlated
with tumor progression as well as decreased survival in
patients with HCC, lung and oral cancer[21-23]. This
Figure 7 (See legend on next page.)
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Figure 7 CD44 not only participated in the FLJ10540 expression, but also modulated osteopontin/FLJ10540-elicited cell growth and
motility in NPC cells. (A) Serum-starved TW01 cells were pre-treated with or without various concentrations of anti-CD44 antibodies for 2 hours;
the cells were then stimulated with 30 ng/ml osteopontin for 30 min. The total protein was extracted from TW01 cells and probed with
antibodies against FLJ10540. β-actin was used as an internal loading control. (B) For the cell proliferation assay, vehicle-TW01, and FLJ10540-TW01
stable transfectants treated with or without osteopontin stimulation combined with anti-CD44 or IgG antibodies were seeded into 96-well plates
with 1.0% FBS. The cells were cultured for 1–3 days followed by MTT assay (OD570) to quantitate cell growth. The data were normalized against
the OD570 value on day 1 of each treatment. The growth curve of TW01 cells are shown as the mean ±s.d. of three independent experiments.
(C) For the migration and invasion assay, vehicle-TW01 and FLJ10540-TW01 stable clones were pre-treated with or without anti-CD44 or IgG
antibodies for 2 hours and seeded into the top of a Transwell insert with or without Matrigel and allowed to adhere for 12 hours. They were
then incubated with or without osteopontin (30 ng/ml) for 3 hours. At the end of the assay, the cells on the topside were scraped, and the cells
that migrated to the bottom were fixed and stained with Giemsa. All of the data represent the mean ±s.d. of three independent experiments.
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http://www.translational-medicine.com/content/10/1/93suggests that FLJ10540 plays an important role in tumor
formation. This is the first time we have shown that
FLJ10540-NPC stable transfectants promoted cell
growth at low serum levels. Conversely, suppressed en-
dogenous FLJ10540 by FLJ10540-mediated siRNA inhib-
ited cell growth, suggesting that FLJ10540 displays a
characteristic associated with oncogenes in NPC. Fur-
thermore, stimulation of FLJ10540-NPC stable cells by
adding osteopontin could encourage cell growth faster
than FLJ10540 alone or the vehicle control. Taken to-
gether, we suggest that FLJ10540, mediated by osteopon-
tin stimulation, may play a significant role in tumor
progression in NPC.
The metastatic spread of cancer cells is composed of
multiple sequential steps such as dys-regulation of inter-
cellular adhesion, degradation of the extracellular matrix,
and increasing cell motility [31]. To the best of our
knowledge, this is the first report to demonstrate that an
increased FLJ10540 expression was not only positively
correlated with clinical advanced N stage, but that is also
promoted NPC cell migration and invasion in vitro.
Moreover, the migratory and invasive abilities were abol-
ished with knockdown endogenous FLJ10540 by siRNA
in NPC cells. Importantly, FLJ10540-NPC transfectants
stimulated by osteopontin enhanced cancer cell migra-
tion and invasion. Our results suggest that one mechan-
ism by which FLJ10540 may promote tumor cell
migration and invasion is through osteopontin regula-
tion in NPC.
We re-arranged a gene expression microarray dataset
and employed the concept of syn-expression to identify
that FLJ10540 is one of the downstream targets of osteo-
pontin in NPC. Recently, it has been reported that osteo-
pontin serves as a serum marker for some human tumor
types [32]. Furthermore, an increased expression of osteo-
pontin has been shown to correlate with disease outcome
and patient survival. Osteopontin is able to engage recep-
tors, including CD44, and thus may stimulate diverse sig-
naling pathways and influence cellular events that in turn,
favor tumorigenesis [33]. Using osteopontin-null mutant
mice as a model system, osteopontin was demonstrated tohave a role in the growth or survival of cancer cells [34].
However, the specific mechanisms by which osteopontin
functions to promote malignant cell behavior have not
been completely elucidated. In the present study, it is cru-
cial to demonstrate that the mRNA and protein expres-
sion levels of FLJ10540 are positively correlated with
osteopontin in NPC specimens. In addition, the expres-
sion level of FLJ10540 was upregulated in an osteopontin
dose-dependent manner in NPC cell lines. The mechan-
isms responsible for the overexpression of FLJ10540 in
malignant cancer cells are still not clear. Here, our results
demonstrated that one of the important upstream regula-
tors of FLJ10540 may be regulated by a cytokine, osteo-
pontin, in NPC cancer cells. Furthermore, blockade of
CD44 receptor caused significant inhibitions of FLJ10540-
induced cell growth, migration and invasion in the pres-
ence of osteopontin stimulation in NPC cells. In this
regard, our results show that CD44 provides an import-
ant link for understanding the role of osteoponint/
FLJ10540 in cell proliferation and metastasis.Conclusions
FLJ10540 was regulated by osteopontin and plays an im-
portant role in NPC because increased FLJ10540 protein
levels are observed to associate with advanced stage of
NPC. In addition, FLJ10540 seems to contribute to tumor
aggressiveness because high FLJ10540 protein levels are
related to reduce patient survival. If the independence
from established prognostic factors is demonstrated in lar-
ger clinical study, FLJ10540 genetic alterations in NPC
may eventually be able to guide therapeutic strategies.Additional file
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